Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,168.00
(
-0.14%
)
Dow Jones
49,490.03
(
0.00%
)
Brent Oil
97.42
(
0.72%
)
Bitcoin
77,786.39
(
-0.58%
)
News Focus
News Focus
Post# of 822509
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Chiugray

Send PM Follow Ignore
Followers 80
Posts 2291
Boards Moderated 0
Alias Born 01/31/2014

Chiugray

Re: SkyLimit2022 post# 762268

Sunday, 04/20/2025 5:14:43 PM

Sunday, April 20, 2025 5:14:43 PM

Post# of 822509
SkyLimit, I would love that to happen. Already NWBO has an entire set of patents, intellectual property, clinical trial data exclusivity, and trade secrets within:
- the DCVax technology platform
- the Flaskworks acquisition
- the in-licensed portfolio from Roswell Park Cancer Center

Likely NWBO already has a "dominant lead" in the dendritic cell IP space for cancer therapy. If they do acquire ImmunoRestoration (DC technology being developed at Moffitt Cancer Center), that dominant lead could easily turn into a dominant position.
Bullish
Bullish

Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News